CD19+CD22 CAR-T

DRUG2 trials

Sponsors

Hebei Senlang Biotechnology Inc., Ltd.

Conditions

Adult B Acute Lymphoblastic LeukemiaRefractory Indolent Adult Non-Hodgkin Lymphoma

Early Phase 1

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Hebei Senlang Biotechnology Inc., Ltd.Refractory Indolent Adult Non-Hodgkin Lymphoma

Start: 2020-04-01End: 2023-03-30Target: 100Updated: 2020-11-13

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Hebei Senlang Biotechnology Inc., Ltd.Adult B Acute Lymphoblastic Leukemia

Start: 2020-04-01End: 2023-05-30Target: 50Updated: 2020-11-13

Related Papers

Safety and Efficacy of CD 19 CAR T Cells (S1904) in Patients with RR B-ALL: A Pooled Analysis of Two Early-Phase Trials

Blood2024-11-05